Inactive Instrument

China Health Industries Holdings, Inc. Stock Other OTC

Equities

CHHE

US1693981045

Pharmaceuticals

Sales 2022 267 Sales 2023 112K Capitalization 14.66M
Net income 2022 - Net income 2023 - EV / Sales 2022 -139,809 x
Net cash position 2022 38.03M Net Debt 2023 5.11M EV / Sales 2023 177 x
P/E ratio 2022
-1.98 x
P/E ratio 2023
-35.9 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 68.71%
More Fundamentals * Assessed data
Dynamic Chart
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2021 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2020 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Full Year Ended June 30, 2020 CI
China Health Industries Holdings, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020 CI
More news
Managers TitleAgeSince
Chief Executive Officer 58 -
Investor Relations Contact - -
Members of the board TitleAgeSince
Chief Executive Officer 58 -
More insiders
China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.
More about the company